Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Exercise is a treatment and therapy tool for lower back pain. You can do many of the exercises and movements in this article ...

For a long time, the Kakeya conjecture, which involves rotating an infinitely narrow needle, kept mathematicians ...

Bank of America upped its price target for Vertex Pharmaceuticals from $555 to $567, signaling growing confidence in the ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...

Vertex Pharmaceuticals (VRTX) is the second stock to buy for the Nasdaq 100 correction. The biotech stock offers stability ...

It's back and it's live. Amazon's Big Spring Sale launched Tuesday morning and will be running through the end of the month. Officials said the sale will have markdowns on must-have items for the ...

Income Availableto Com Excl Extra Ord 0.47-0.55 0.28 0.67 Income Availableto Com Incl Extra Ord 0.47-0.55 0.28 0.67 ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $512.52, indicating a +0.06% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 1.08%.

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years ...

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years, therapeutic ...